Good morning,
We have 13 deals this week, taking in Spire Healthcare's £1 billion takeover by a Toscafund-led consortium and Grifols' €160 million plasma fractionation plant groundbreaking near Barcelona. Let's hop into it.
In today's free edition:
🇬🇧 Spire Healthcare recommends £1 billion takeover by Toscafund-led consortium
🇪🇸 Grifols breaks ground on €160 million plasma plant in Catalonia
🔒 For paying members only:
🇩🇪 Biotech start-up moves into wet-lab space in North Rhine-Westphalia
🇬🇧 Clinical-stage biotech becomes first occupier at Oxfordshire lab hub
🇪🇸 UK biotech joins Catalonia life sciences ecosystem
🇬🇧 Imperial spinout takes lab space at London innovation hub
🇮🇹 Contract manufacturer progresses major expansion in Lazio
🇬🇧 Biomanufacturer opens major expansion in North East England
🇪🇸 Contract manufacturer expands in Castile and León
🇬🇧 Investor acquires two private hospitals in off-market sale
🇪🇸 Eli Lilly accelerates expansion at Madrid-region complex
🇪🇸 Esteve advances API expansion in Catalonia
🇨🇭 Lonza continues major fill-finish facility build in Aargau
Subscribe here to unlock.
Enjoy today's newsletter,
— Stephen Ryan
🇬🇧 Spire Healthcare recommends £1 billion takeover by Toscafund-led consortium
Spire Healthcare Group has recommended a c.£1 billion takeover by a consortium indirectly owned by Toscafund Asset Management, Three Hills and Ares Management, acquiring the business through the newly formed Tulip UK Bidco vehicle.
Candesic provided commercial due diligence to the consortium, with the deal following a strategic review launched by Spire last September that included discussions with several interested parties.
Spire is the UK's largest independent hospital operator by revenue, operating 38 hospitals across England, Scotland and Wales.
🇪🇸 Grifols breaks ground on plasma fractionation plant near Barcelona
Grifols held the groundbreaking for a new plasma fractionation plant at Lliçà de Vall (Barcelona), attended by Prime Minister Pedro Sánchez and industry and tourism minister Jordi Hereu in June 2026.
The initial phase is a €160 million investment, with operations starting in 2030 and adding 3 million litres/year of fractionation capacity for the more than 300,000 European patients who depend on plasma-derived therapies.
The site will integrate with Grifols' existing complex at neighbouring Parets del Vallès to form a single 25-hectare biotechnology campus housing 3,700+ employees, 400 of them new.
The facility — fractionation plant plus QC labs, warehouses and logistics areas, designed and built in-house by Grifols Engineering — is designated a strategic project by the Generalitat and conceived as a smart factory running on 100 per cent renewable electricity.
Like what you've just read? There are 1,949 more where that came from.
Today's two free stories are just a taster. Premium members get all the deals this week, every week, plus full access to our database of 1,949 life sciences real estate deals across the UK and Europe, built from over four years of continuous tracking.
Filter by country, deal type, asset size, value or dealmaker. Search any record in seconds. Spot the trends, find the players, move before your competitors do.
To access this unique dataset, upgrade to Premium.
